You just read:

Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia (HoFH)

News provided by

Regeneron Pharmaceuticals, Inc.

Apr 06, 2017, 07:00 ET